CLASRP

CLASRP (Clk4-associating SR-related protein) is a nuclear SR-related splicing regulatory protein that links CDC-like kinase (Clk) activity to alternative splicing control (PMID:12169693). It was identified as a partner that binds the kinase-inactive Clk4 K189R mutant but not the active wild-type kinase, and its long isoform localizes to nuclear dots where it sequesters Clk4 K189R and drives exon EB inclusion from Clk1 pre-mRNA (PMID:12169693). Beyond this kinase association and splicing readout, CLASRP functions within a Clk-dependent pathway promoting cell proliferation, migration, and invasion: in colorectal cancer cells its pro-tumorigenic effects are abolished by Clk inhibitors, which lower CLASRP levels and trigger caspase-3/8-mediated apoptosis (PMID:37658940). Its expression is transcriptionally driven through a LINC00482/E2F1 axis, with E2F1 recruited to the CLASRP promoter to enhance expression and confer cisplatin resistance in NSCLC cells (PMID:37966662). The biochemical mechanism by which CLASRP itself recognizes RNA or remodels spliceosome assembly has not been characterized in the available corpus.

1. 2002 Medium

   Established CLASRP as a physical link between the Clk4 kinase and the splicing machinery, defining an isoform-specific nuclear regulator of alternative splicing.

   Evidence Yeast two-hybrid and in vitro interaction assays with Clk4 K189R, HA-tagged localization imaging, and Clk1 alternative splicing reporter in cells

   PMID:12169693

   Open questions at the time

   • No structural or domain-level basis for preferential binding to kinase-inactive Clk4 identified
   • Direct RNA-binding activity of CLASRP and the spliceosomal step it acts on not defined
   • Whether CLASRP is a Clk substrate or a scaffold left unresolved
2. 2023 Medium

   Placed CLASRP functionally downstream of Clk activity as a driver of tumor cell proliferation, migration, and invasion whose effects depend on Clk signaling.

   Evidence Gain- and loss-of-function in colorectal cancer cells, xenograft model, Clk inhibitor treatment, and caspase-3/8 cleavage western blotting

   PMID:37658940

   Open questions at the time

   • Specific splicing targets mediating the pro-tumorigenic phenotype not identified
   • Whether Clk inhibitors act directly on CLASRP-Clk complexes or through broader Clk effects unclear
3. 2023 Medium

   Defined the upstream transcriptional control of CLASRP, showing a LINC00482/E2F1 axis drives its expression and contributes to chemoresistance.

   Evidence Dual-luciferase reporter, ChIP, and RIP assays plus knockdown/rescue and xenograft in NSCLC cells with cisplatin sensitivity readout

   PMID:37966662

   Open questions at the time

   • Mechanism by which CLASRP confers cisplatin resistance at the molecular level not established
   • Whether the splicing function of CLASRP underlies its drug-resistance role untested

• The intrinsic biochemical activity of CLASRP — how it binds RNA, which spliceosome components it engages, and the splice events it controls genome-wide — remains undefined.
• No genome-wide map of CLASRP-regulated splicing events
• No reconstitution of CLASRP within a defined splicing reaction
• Relationship between Clk binding, nuclear dot formation, and catalytic splicing outcome unresolved